Ruben Rhoades
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruben Rhoades has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Adam G. Mermelstein
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA
1 shared publication - Amy Yang
College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA
1 shared publication Brandi Thoma
Deparment of Pharmacy, Thomas Jefferson University, Philadelphia, PA, United States of America
1 shared publication- Connor McLaughlin
Thomas Jefferson University Hospital
1 shared publication Diana Tzeng
Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States
1 shared publication- Douglass Drelich
CSL Behring, King of Prussia, USA
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in Annals of Hematology
An unusual trigger for a rare hemolytic anemia: paroxysmal cold hemoglobinuria after shingles and COVID-19
Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that commonly presents as a transient, post-infectious disease mediated by biphasic Donath-Landsteiner antibodies, which bind to red blood cells at cold temperatures but cause hemolysis at core body temperature. PCH is less common in adults but can be a complication of infection or hematologic malignancy. One viral trigger of PCH that has rarely been described is that of primary varicella-zoster virus (VZV). Here, we report the case of a 69-year-old man who developed severe PCH following an episode of shingles, raising the possibility of a temporal relationship between PCH and VZV reactivation. Erythrophagocytosis and rosetting of red blood cells around neutrophils, smear findings commonly seen in PCH, were observed on the patient’s blood smear and aided in our diagnosis. Initial hemolysis testing demonstrated complement component 3-positive, immunoglobulin G-negative direct antiglobulin testing. Donath-Landsteiner testing confirmed a diagnosis of PCH. The patient had a complicated 38-day hospital course that required mechanical ventilation, renal replacement therapy, and extensive transfusions. Notably, the patient was also diagnosed with COVID-19 shortly before the onset of hemolysis, representing a potential alternative trigger or co-trigger to his PCH. Although the clinical timeline is compatible with VZV reactivation triggering PCH, the specific infectious trigger cannot be definitively established. Nevertheless, to our knowledge, this is the first reported case of PCH occurring in temporal association with VZV reactivation rather than primary VZV infection.
- 9 October 2026
- Published by Springer Nature in Annals of Hematology
Open AccessAn unusual trigger for a rare hemolytic anemia: paroxysmal cold hemoglobinuria after shingles and COVID-19
Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that commonly presents as a transient, post-infectious disease mediated by biphasic Donath-Landsteiner antibodies, which bind to red blood cells at cold temperatures but cause hemolysis at core body temperature. PCH is less common in adults but can be a complication of infection or hematologic malignancy. One viral trigger of PCH that has rarely been described is that of primary varicella-zoster virus (VZV). Here, we report the case of a 69-year-old man who developed severe PCH following an episode of shingles, raising the possibility of a temporal relationship between PCH and VZV reactivation. Erythrophagocytosis and rosetting of red blood cells around neutrophils, smear findings commonly seen in PCH, were observed on the patient’s blood smear and aided in our diagnosis. Initial hemolysis testing demonstrated complement component 3-positive, immunoglobulin G-negative direct antiglobulin testing. Donath-Landsteiner testing confirmed a diagnosis of PCH. The patient had a complicated 38-day hospital course that required mechanical ventilation, renal replacement therapy, and extensive transfusions. Notably, the patient was also diagnosed with COVID-19 shortly before the onset of hemolysis, representing a potential alternative trigger or co-trigger to his PCH. Although the clinical timeline is compatible with VZV reactivation triggering PCH, the specific infectious trigger cannot be definitively established. Nevertheless, to our knowledge, this is the first reported case of PCH occurring in temporal association with VZV reactivation rather than primary VZV infection.
- 2 July 2026
- Published by Springer Nature
- p. 59-71
Hemoglobin: The Ideal Conveyor of Oxygen
- Open Access
- 5 October 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (2) , 462-471
Clinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: A 5-Year retrospective study
Hereditary thrombophilia testing is frequently ordered after venous thromboembolism (VTE), despite little evidence of clinical utility and most guidelines cautioning against testing. We conducted a retrospective, observational study of inpatient hereditary thrombophilia testing ordered during a hospital admission for acute VTE between 2019 and 2024. We aimed to characterize patterns of testing results, and costs, and to evaluate whether younger patients and those with unprovoked VTE were more likely to test positive for hereditary thrombophilia. A total of 835 hereditary thrombophilia tests – including those for factor V Leiden, prothrombin G20210A , deficiencies of protein S, protein C, and antithrombin, hyperhomocysteinemia, and plasminogen activator inhibitor-1 excess – were ordered in 220 patients. Overall, 19.6% of results were abnormal, and 45.0% of patients had at least one abnormal result. There was no difference in the rate of positive results among patients with provoked vs. unprovoked VTE (30.7% vs. 34.5%, p = .554) nor patients < 50 vs. ≥ 50 years of age (33.1% vs. 32.4%, p = .912). Only 4/99 (4.0%) patients with an abnormal result had their clinical management clearly changed due to the result. The tests totaled $385,161 USD in institutional charges and $26,029 USD in Medicare fees. Inpatient hereditary thrombophilia testing during admission for acute VTE is low yield, with frequent abnormal results, many of which likely represented false positives, and minimal impact on clinical management with high costs. Graphical abstract
- 5 October 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (2) , 462-471
Open AccessClinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: A 5-Year retrospective study
Hereditary thrombophilia testing is frequently ordered after venous thromboembolism (VTE), despite little evidence of clinical utility and most guidelines cautioning against testing. We conducted a retrospective, observational study of inpatient hereditary thrombophilia testing ordered during a hospital admission for acute VTE between 2019 and 2024. We aimed to characterize patterns of testing results, and costs, and to evaluate whether younger patients and those with unprovoked VTE were more likely to test positive for hereditary thrombophilia. A total of 835 hereditary thrombophilia tests – including those for factor V Leiden, prothrombin G20210A , deficiencies of protein S, protein C, and antithrombin, hyperhomocysteinemia, and plasminogen activator inhibitor-1 excess – were ordered in 220 patients. Overall, 19.6% of results were abnormal, and 45.0% of patients had at least one abnormal result. There was no difference in the rate of positive results among patients with provoked vs. unprovoked VTE (30.7% vs. 34.5%, p = .554) nor patients < 50 vs. ≥ 50 years of age (33.1% vs. 32.4%, p = .912). Only 4/99 (4.0%) patients with an abnormal result had their clinical management clearly changed due to the result. The tests totaled $385,161 USD in institutional charges and $26,029 USD in Medicare fees. Inpatient hereditary thrombophilia testing during admission for acute VTE is low yield, with frequent abnormal results, many of which likely represented false positives, and minimal impact on clinical management with high costs. Graphical abstract
- 5 July 2025
- Published by Springer Nature
- p. 1-16
COVID-19 and Pulmonary Embolism: Incidence and Pathophysiology
- 5 July 2025
- Published by Springer Nature
- p. 1-16
COVID-19 and Pulmonary Embolism: Incidence and Pathophysiology
- Open Access
- 1 January 2025
- Published by Thomas Jefferson University
- Vol. 26 (1) , 24
An Unusual Complication of Metastatic Colorectal Cancer: Port-Site Hematoma as the First Sign of Bone Marrow Involvement and Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC) is a life-threatening condition marked by a spectrum of thrombosis due to activation of procoagulant factors and bleeding due to eventual consumption of these factors. DIC invariably occurs secondary to an underlying condition, including infection, inflammatory conditions, trauma, and malignancies. Treatment of DIC primarily involves treatment of the underlying cause.1 Bone marrow invasion occurs when tumor cells infiltrate the hematopoietic marrow space, displacing progenitor cells and causing cytopenias. This process is distinct from bone metastases, where malignant cells spread to the cortical or trabecular bone, typically causing bone pain, pathologic fractures, or hypercalcemia. Disseminated carcinomatosis of the bone marrow (DCBM) is a particularly severe form of marrow involvement, characterized by widespread and uniform infiltration that can result in profound cytopenias, marrow failure, and DIC.2,3 Cancers most commonly associated with bone marrow invasion include prostate, lung, breast, and gastric malignancies. While gastric cancer rarely metastasizes to bone, it is frequently cited as a malignancy associated with marrow infiltration. In contrast, metastatic colorectal cancer rarely presents with DCBM leading to DIC.4,5 We present a case of a patient with metastatic colon cancer who developed acute anemia due to a large port-site hematoma. Further investigation revealed DCBM, rising carcinoembryonic antigen (CEA) levels, and DIC. In this case report, we outline the clinical course and management of this patient. Additionally, we review published cases of this rare pathology, providing insights into its presentation and clinical implications.
- 1 January 2025
- Published by Thomas Jefferson University
- Vol. 26 (1) , 24
Open AccessAn Unusual Complication of Metastatic Colorectal Cancer: Port-Site Hematoma as the First Sign of Bone Marrow Involvement and Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC) is a life-threatening condition marked by a spectrum of thrombosis due to activation of procoagulant factors and bleeding due to eventual consumption of these factors. DIC invariably occurs secondary to an underlying condition, including infection, inflammatory conditions, trauma, and malignancies. Treatment of DIC primarily involves treatment of the underlying cause.1 Bone marrow invasion occurs when tumor cells infiltrate the hematopoietic marrow space, displacing progenitor cells and causing cytopenias. This process is distinct from bone metastases, where malignant cells spread to the cortical or trabecular bone, typically causing bone pain, pathologic fractures, or hypercalcemia. Disseminated carcinomatosis of the bone marrow (DCBM) is a particularly severe form of marrow involvement, characterized by widespread and uniform infiltration that can result in profound cytopenias, marrow failure, and DIC.2,3 Cancers most commonly associated with bone marrow invasion include prostate, lung, breast, and gastric malignancies. While gastric cancer rarely metastasizes to bone, it is frequently cited as a malignancy associated with marrow infiltration. In contrast, metastatic colorectal cancer rarely presents with DCBM leading to DIC.4,5 We present a case of a patient with metastatic colon cancer who developed acute anemia due to a large port-site hematoma. Further investigation revealed DCBM, rising carcinoembryonic antigen (CEA) levels, and DIC. In this case report, we outline the clinical course and management of this patient. Additionally, we review published cases of this rare pathology, providing insights into its presentation and clinical implications.
- 24 August 2023
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (10) , 107308
Low value of inherited thrombophilia testing among patients with stroke or transient ischemic attack: A three-year retrospective study
- 24 August 2023
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (10) , 107308
Low value of inherited thrombophilia testing among patients with stroke or transient ischemic attack: A three-year retrospective study
- Open Access
- 1 January 2023
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 29
Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center
Persons with bleeding disorders (PwBD) are at high risk for bleeding with invasive procedures. However, the risk of bleeding in PwBD undergoing major surgery and outcomes of patients managed perioperatively at a hemophilia treatment center (HTC) are not well described. We performed a retrospective review of surgical outcomes among PwBD undergoing major surgery between January 1st, 2017 and December 31st, 2019 at the Cardeza Foundation Hemophilia and Thrombosis Center in Philadelphia, PA. The primary outcome was postoperative bleeding, assessed according to the ISTH-SSC's 2010 definition. Secondary outcomes included use of unplanned postoperative hemostatic therapy, LOS, and 30-day readmission rate. Results were compared to non-PwBD population from a surgical database, matched for surgery, age, and sex. During the study period, 50 PwBD underwent 63 major surgeries. The most common diagnoses were VWD (64%) and hemophilia A (20.0%). The most common surgical procedure category was orthopedic (33.3%), predominantly arthroplasties. Postoperatively,4.8% of procedures were complicated by major bleeding and 1.6% by non-major bleeding. The mean LOS was 1.65 days, and 30-day readmission rate was 1.6%. In comparison to matched, non-PwBD patients in a national surgical database undergoing the same procedures, study patients had a similar rate of bleeding complications per procedure (5.0% vs 1.04% P = .071, Fisher's exact test). PwBD undergoing major surgeries have low rates of major bleeding when receiving comprehensive care at an HTC. Bleeding and hospital readmission rates were similar to non-PwBD baseline in a large database.
- 1 January 2023
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 29
Open AccessPerioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center
Persons with bleeding disorders (PwBD) are at high risk for bleeding with invasive procedures. However, the risk of bleeding in PwBD undergoing major surgery and outcomes of patients managed perioperatively at a hemophilia treatment center (HTC) are not well described. We performed a retrospective review of surgical outcomes among PwBD undergoing major surgery between January 1st, 2017 and December 31st, 2019 at the Cardeza Foundation Hemophilia and Thrombosis Center in Philadelphia, PA. The primary outcome was postoperative bleeding, assessed according to the ISTH-SSC's 2010 definition. Secondary outcomes included use of unplanned postoperative hemostatic therapy, LOS, and 30-day readmission rate. Results were compared to non-PwBD population from a surgical database, matched for surgery, age, and sex. During the study period, 50 PwBD underwent 63 major surgeries. The most common diagnoses were VWD (64%) and hemophilia A (20.0%). The most common surgical procedure category was orthopedic (33.3%), predominantly arthroplasties. Postoperatively,4.8% of procedures were complicated by major bleeding and 1.6% by non-major bleeding. The mean LOS was 1.65 days, and 30-day readmission rate was 1.6%. In comparison to matched, non-PwBD patients in a national surgical database undergoing the same procedures, study patients had a similar rate of bleeding complications per procedure (5.0% vs 1.04% P = .071, Fisher's exact test). PwBD undergoing major surgeries have low rates of major bleeding when receiving comprehensive care at an HTC. Bleeding and hospital readmission rates were similar to non-PwBD baseline in a large database.
- 1 July 2021
- Published by Elsevier in Thrombosis Research
- Vol. 203, 1-4
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
- 1 July 2021
- Published by Elsevier in Thrombosis Research
- Vol. 203, 1-4
Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
- Open Access
Development and Validation of Postoperative Venous Thromboembolism risk prediction model
Background: VTE is a serious postoperative complication after surgery with resultant higher morbidity and mortality. Despite years of experience with current risk models, rates continue to be high and more information is needed on individual patient risk in the prophylaxis era. Research Questions: Can we assess the individualized risk of postoperative venous thromboembolism (VTE) for broad categories of surgery? Methods: This study was performed using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Database. Patient data (n=2,875,190) from 2015-2017 were used for study analysis. Eight predictors were selected for the model: age, preoperative platelet count≥450 (×10 9 /L), disseminated cancer, corticosteroid use, serum albumin ≤2.5 g/dL, preoperative sepsis, hospital length of stay and surgery type. The second model included 7 predictors without hospital length of stay. A predictive model was trained using ACS-NSQIP data from 2015-2016 (n=1,859,227) and tested using data from 2017 (n= 1,015,963). Primary outcomes are postoperative 30-day VTE, including deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Results: VTE occurred in 23,249 patients (0.81%) and 49.9% of VTE occurred after discharge from index hospitalization. The risk prediction model had high AUC (area under the receiver operating characteristic curve) for postoperative VTE of 0.78 (training cohort) and 0.78 (test cohort). Interpretation: This clinical prediction model is a validated, practical and easy-to-use tool to identify surgical patients at the highest risk of postoperative VTE and provide an individualized assessment of risk based on clinical factors and type of surgery. This prediction model may be used as a tool to assess individualized risk of postoperative VTE and promote broader discussion and awareness of the VTE risk during the perioperative period.
Open AccessDevelopment and Validation of Postoperative Venous Thromboembolism risk prediction model
Background: VTE is a serious postoperative complication after surgery with resultant higher morbidity and mortality. Despite years of experience with current risk models, rates continue to be high and more information is needed on individual patient risk in the prophylaxis era. Research Questions: Can we assess the individualized risk of postoperative venous thromboembolism (VTE) for broad categories of surgery? Methods: This study was performed using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Database. Patient data (n=2,875,190) from 2015-2017 were used for study analysis. Eight predictors were selected for the model: age, preoperative platelet count≥450 (×10 9 /L), disseminated cancer, corticosteroid use, serum albumin ≤2.5 g/dL, preoperative sepsis, hospital length of stay and surgery type. The second model included 7 predictors without hospital length of stay. A predictive model was trained using ACS-NSQIP data from 2015-2016 (n=1,859,227) and tested using data from 2017 (n= 1,015,963). Primary outcomes are postoperative 30-day VTE, including deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Results: VTE occurred in 23,249 patients (0.81%) and 49.9% of VTE occurred after discharge from index hospitalization. The risk prediction model had high AUC (area under the receiver operating characteristic curve) for postoperative VTE of 0.78 (training cohort) and 0.78 (test cohort). Interpretation: This clinical prediction model is a validated, practical and easy-to-use tool to identify surgical patients at the highest risk of postoperative VTE and provide an individualized assessment of risk based on clinical factors and type of surgery. This prediction model may be used as a tool to assess individualized risk of postoperative VTE and promote broader discussion and awareness of the VTE risk during the perioperative period.
- 14 March 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (3) , e226755
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient
Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. The neoplastic cells displayed a plasmacytoid appearance, with the expression of CD38 and CD138, and were positive for EBV by in situ hybridisation for EBV-encoded RNA. Systemic workup revealed the presence of Kaposi sarcoma, but no evidence of lymphoma. He is currently being treated with high-dose methotrexate, as well as antiretroviral therapy for his HIV infection, and has achieved a complete response.
- 14 March 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (3) , e226755
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient
Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. The neoplastic cells displayed a plasmacytoid appearance, with the expression of CD38 and CD138, and were positive for EBV by in situ hybridisation for EBV-encoded RNA. Systemic workup revealed the presence of Kaposi sarcoma, but no evidence of lymphoma. He is currently being treated with high-dose methotrexate, as well as antiretroviral therapy for his HIV infection, and has achieved a complete response.